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Abstract
The chronic shortage of human donor organs and tissues for allotransplantation could be relieved if clinical xenotransplantation were to
become a viable clinical therapy. Balanced against the benefits of xenotransplantation are the possible consequences of zoonotic infections,
and in particular, infection by porcine endogenous retrovirus (PERV). An often-proclaimed risk of PERV infection is the possible
recombination of PERV with human endogenous retroviruses (HERV) (Lee et al., 2002). To address this issue, we examined the potential
for HERV sequences to be cross-packaged into PERV particles produced from infected human 293 cells. Although HERV-K, W, E, R, and
ERV-9 RNA transcripts are expressed in 293 cells, we did not detect cross-packaging of any of these HERV groups. Quantitative analysis
indicated that less than approximately 1 in 104–107 PERV particles might contain HERV sequences. In comparison, we found that murine
leukemia virus (MLV)-based vector transcripts were cross-packaged at a rate of approximately one copy in 104 PERV particles. Our results
indicate that the potential for recombination of PERV and HERV sequences is low and that novel viruses generated by this mechanism are
unlikely to represent a significant risk for xenotransplantation.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Xenotransplantation of porcine organs has the potential to
overcome the severe shortage of human tissues and organs
available for human transplantation (Sachs et al., 2001). How-
ever, this procedure also carries with it a number of important
microbiological safety issues relating to the possible infection
of a xenotransplant recipient with a zoonotic microorganism
(Weiss et al., 2000). Encouragingly, many exogenous micro-
organisms of pigs can be eliminated from donor animals by the
use of barrier derivation procedures (Tucker et al., 2002). In
contrast, because porcine endogenous retrovirus (PERV) is
part of the germ line DNA of pigs and is therefore unaffected
by such procedures, its control is more challenging. In this
article we investigate a possible consequence resulting from
the infection of a human cell by PERV, namely, the potential
generation of novel infectious viruses via the cross-packaging
and recombination of PERV and human endogenous retrovirus
(HERV) sequences.
Endogenous retroviruses (ERVs) are present in the ge-
nomes of all vertebrates. They are a diverse group of ele-
ments whose gene organization is very similar to that of
exogenous retroviruses (Boeke and Stoye, 1997; Stoye,
2001; Wilkinson et al., 1994). At the nucleotide level, ERVs
can have homology to -retroviruses (e.g., murine leukemia
viruses, MLV) (Akiyoshi et al., 1998; Armstrong et al.,
1971; Patience et al., 2001; Wilkinson et al., 1994), as well
as -retroviruses (e.g., mouse mammary tumor virus) (Erics-
son et al., 2001; Patience et al., 2001; Wilkinson et al.,
1994), but share little or no homology to lentiviruses (e.g.,
human immunodeficiency virus) (Horwitz, et al., 1992).
Although multiple copies of ERV are present in the genome
of their host, the majority of these loci are not replication
competent due to point mutations or deletions disrupting
one or more of the three main open reading frames (ORFs);
gag, pol, and env (Wilkinson et al., 1994). Nevertheless,
some ERV loci have retained the ability to encode one or
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more viral proteins and can, on occasion, produce infectious
particles. PERV is one example of an infectious ERV (Pa-
tience et al., 1997; Wilson et al., 1998).
The genomic DNA of pigs contains at least 13 groups of
PERV that are related to - and -retroviruses (Ericsson et
al., 2001; Klymiuk et al., 2002; Patience et al., 2001).
Infectious PERV are thought to be limited to only one of
these groups, as members of the remaining groups have
extensive ORF disruptions (Ericsson et al., 2001; Klymiuk
et al., 2002; Patience et al., 2001). Within this group, three
infectious PERV subgroups have been identified, PERV-A,
-B, and -C (Takeuchi et al., 1998). PERV-A and -B can
infect human and porcine cells (Takeuchi et al., 1998).
PERV-C is more limited in its tropism and can infect only
porcine cells (Oldmixon et al., 2002; Takeuchi et al., 1998).
Recombination between PERV can occur and can result in
the formation of high-titer PERV isolates (Oldmixon et al.,
2002; Wilson et al., 2000). Although PERV is infectious for
certain human cells in vitro, no infection of xenotransplant
recipients following clinical transplantation has been de-
tected (Dinsmore et al., 2000; Elliott et al., 2000; Heneine et
al., 1998; Paradis et al., 1999; Patience et al., 1998a).
The human genome also contains ERVs related to - and
-retroviruses (Wilkinson et al., 1994). All HERV loci iden-
tified to date possess at least one defective ORF and are
therefore not infectious (Tristem, 2000). However, some
HERV groups such as HERV-E, HERV-R, ERV-9, HERV-H,
HERV-W, and HERV-K possess either complete or near com-
plete ORFs for one or more of their component genes and are
also widely expressed in primary human cells (Wilkinson et
al., 1994). If human cells were to become infected by PERV,
these HERV groups would be the most likely substrates for the
generation of novel recombinant viruses.
To date, the risk of HERV recombination with PERV has
been the subject of debate, but little research. Theoretically,
HERV–PERV recombination could occur during the integra-
tion of PERV into the human genomic DNA following the
infection of a cell by PERV. Much more likely is the genera-
tion of HERV–PERV recombinants during a productive infec-
tion following the copackaging of a HERV and PERV
genomic transcript into an individual retrovirus particle (Tele-
snitsky and Goff, 1997). Thus, the demonstration of cross-
packaging of HERV sequences into PERV particles would
reflect an increased probability of recombination between these
viruses, and ultimately, an increased potential for the genera-
tion of chimeric viruses with unpredictable pathogenicities. In
this article we examine the potential for HERV transcripts to
be packaged into PERV particles using a sensitive in vitro
assay system.
Results
Comparison of PERV replication in human cell lines
To maximize the potential to detect cross-packaging of
HERV sequences by PERV, the human cell line must sup-
port PERV replication to high titer. To date, only three
human cell lines have been identified that support PERV
replication: 293 cells (Patience et al., 1997), HepG2 cells
(Wilson et al., 2000), and to a lesser extent HeLa cells
(Wilson et al., 2000). We compared PERV replication in
293 and HepG2 cells using a PERV-A isolate that grows to
high titers in vitro (PERV-A 14/220) (Oldmixon et al.,
2002; Sachs et al., 1976). PERV-A 14/220 is a PERV-A/
PERV-C recombinant isolate, identified during an in vitro
transmission assay using PBMC from Massachusetts Gen-
eral Hospital major histocompatibility complex (MHC)-in-
bred miniature swine (Oldmixon et al., 2002; Sachs et al.,
1976). We found that the culture supernatant of 293 cells
infected with PERV-A 14/220 contained approximately
200-fold more RT activity than the equivalent HepG2 su-
pernatant (55,000 and 230 mU/ml, respectively). These re-
sults indicate that based on the greater production of PERV
particles, 293 cells are more appropriate than HepG2 cells
for the study of HERV cross-packaging by PERV.
HERV expression in human cells
To most stringently examine the potential for HERV–
PERV recombination, it is essential that (1) the RT-PCR
method is capable of detecting transcripts from as many
individual loci within a HERV family as possible and (2)
the PERV-infected human cell line expresses a wide spec-
trum of HERV sequences. We investigated the HERV ex-
pression profile in 293 and HepG2 cells by RT-PCR and
Northern blot. The sensitivity of the RT-PCRs was maxi-
mized using primers designed toward conserved sequences
within a number of biologically significant HERV groups
(Table 1). A phylogenetic comparison of these HERV
groups is presented in Fig. 1A. We found that 293 cells
express HERV-E, HERV-R, ERV-9, HERV-H, HERV-W,
and HERV-K RNA transcripts at levels comparable to
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
RNA (Fig. 1B). By Northern blot, we found that 293 cells
express multiple transcripts for each HERV family (Fig.
1C). Although HepG2 cells expressed RTVL-H and ERV-9
sequences at similar levels to 293 cells, expression of the
remaining HERV groups in HepG2 cells was either lower
than 293 cells (HERV-E and HERV-W) or was not detected
(HERV-R) (data not shown). Thus, based on their broader
HERV expression profile, 293 cells appeared more suitable
than HepG2 for the study of HERV cross-packaging by
PERV.
Analysis of PERV particles for presence of HERV RNA
We concentrated and purified PERV particles from the
supernatant of 293/PERV-A cells using sucrose density
gradient centrifugation. The RT activity profile of the gra-
dient is shown in Fig. 2A and demonstrates that the RT
activity of the peak gradient fraction was increased approx-
imately 200-fold, i.e., 1.9  106 mU/ml for the peak gra-
dient fraction in comparison to 5.5  103 mU/ml for un-
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concentrated culture supernatant. Most PERV particles
banded at a density of approximately 1.14–1.17 g/ml, i.e. a
value consistent with mature PERV particles and other
C-type retroviruses (Tacke et al., 2000).
To test for HERV transcripts in these PERV particles, we
synthesized a random-primed cDNA from the RNA of
pooled peak fractions (spanning the density range 1.14–
1.17 g/ml) and analyzed this cDNA by RT-PCR. While high
levels of PERV RNA were present in the peak fractions, in
marked contrast, HERV RNAs were not detected (Fig. 2B).
PERV is known to be capable of cross-packaging MLV-
based vectors (Takeuchi et al., 1998). Therefore, for com-
parison, we examined the ability of PERV particles to cross-
package the MLV-derived -galactosidase (LacZ) reporter
vector MFGnlsLacZ. We transduced 293/PERV-A cells at
high m.o.i. with MFGnlsLacZ vector and purified particles
from the supernatant of these cells by sucrose gradient
centrifugation. In contrast to our results with HERV, we
detected significant levels of MLV-based vector transcripts
in the PERV particles (Fig. 2C).
Determination of the ratio of PERV:HERV sequences in
PERV particles
To determine the ratios of PERV:HERV and PERV:
MLV-vector transcripts present in PERV particles, we de-
termined the concentration of HERV, PERV, and vector
RNAs present in the peak gradient fraction. Having deter-
mined the dilution to which the peak fraction RNA could be
taken before becoming undetectable by RT-PCR (Fig. 2C),
we then determined the sensitivity of the individual RT-
PCR reactions using in vitro transcribed RNAs (Table 2). It
is noteworthy that while typical sensitivities of the RT-
PCRs were approximately 1 pg per reaction, the assays for
PERV and HERV-K were less sensitive (detecting approx-
imately 0.1–1.0 ng per reaction). From these results, we
were able to calculate the concentration of RNAs present in
the peak fraction. For example, RNA from the peak gradient
fraction could be diluted approximately 1024-fold before
PERV became undetectable by RT-PCR (Fig. 2C). As the
sensitivity of the PERV pol RT-PCR was 1.25 ng per
reaction, we calculated that the peak fraction contained 1.28
g of PERV RNA (Table 2). Similarly, we calculated that
the peak fraction contained 100 pg of MLV vector RNA,
and therefore, a LacZ:PERV ratio of approximately
1:38,000. We calculated that 1:51,000 (for HERV-K)
down to 1:1,000,000 (for the remaining HERV families)
Table 1
Primers and PCR conditions used to detect HERV and PERV sequences
HERV group (gene) GenBank Accession No. Sense primer, antisense primer
PERV (Pol) AF038599 TGCAGGAAACCTCGAGACTC, TAACGTGGGATGCATGGATC
HERV-H (Pol) K01891 CCTCACCCTGATCACRYTTG, GAATAATGTCTGACAGAAGGG
HERV-W (Pol) AF009668 AATTATCCAAAGGCACCAGGG, TGTGTAAGGACTCCTAGAGC
HERV-E (Pol) M10976 TGGCAACTAAGTGGCTACAGG, ATTTGTAGTCTTTTGAGCCCC
ERV-9 (Pol) X57147 CCTGAAGCTCATAAAGGATTAC, CATCTGAAGGAACAGAGTGCC
HERV-R (Env) M12140 TGCCAGATAGTATCCATGGG, TCTTCATCGCTGACTCGTGC
HERV-K (Pol) M14123 CCAGGTTTCAGTGGAAAGTG, GTCTCCTCTTAAGATAGAGAAC
LacZ CTCTGGCTCACAGTACGCGTAGG
CCATCAATCCGGTAGGTTTTCCG
Fig. 1. HERV profile of 293 cells. (A) Phylogenetic comparison of HERV
and PERV sequences. (B) HERV expression in 293 cells. Lanes: M,
marker; H, HERV-H; W, HERV-W; E, HERV-E, R, HERV-R; 9, ERV-9;
G, GAPDH; M. RT-PCR for each HERV group was performed using a
random-primed cDNA prepared from 293 cell RNA (Trizol, Invitrogen
Life Technologies). The absence of contaminating DNA in the RNA
preparation was confirmed by PCR analysis of RNA that had not been
subjected to reverse transcription. HERV-K expression was also detected
in a separate experiment (data not shown). (C) Multiple HERV RNA
transcripts are expressed in 293 cells. The RNA transcript profile of 293
cells was determined by Northern blot using high-stringency wash condi-
tions to maintain probe specificity.
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PERV particles contained a HERV transcript (Table 2).
Minimum concentrations and ratios of the transcripts are
presented because HERV RNAs were not detected.
Discussion
In this article we examine the potential for recombination
between PERV and HERV following cross-packaging. De-
monstrable cross-packaging might reflect an increased po-
tential for the generation of chimeric viruses. The clinical
consequences of such recombination are unpredictable, but
could, in a worst case scenario, generate novel viruses with
potential to cause human disease.
We designed an in vitro system to investigate HERV–
PERV recombination based on the assumption that the po-
tential for recombination is greatest if two distinct retroviral
transcripts are copackaged into individual virus particles.
Therefore, to provide as diverse an analysis as possible, we
required that the infected human cell line used in this study
should (1) express a broad spectrum of HERV and (2) be
productively infectable by PERV. We found that 293 cells
Fig. 2. Analysis of sucrose gradient-purified PERV particles. (A) RT activity of sucrose gradient-purified 293/PERV-A supernatant. (B) RT-PCR for PERV
and HERV sequences in peak gradient fractions produced from 293/PERV-A cells. (C) RT-PCR for PERV pol and MLV-based vector transcripts using
dilutions of RNA purified from the peak sucrose-gradient fraction of 293/PERV-A cells and 293/PERV-A/LacZ cells. PERV production from these cell lines
was comparable, i.e., within three-fold according to PERV pol RT-PCR (data not shown). No amplicon for PERV pol was detected at a 1:4096 dilution of
the gradient RNA.
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expressed a wide range of HERV transcripts, including long
transcripts of HERV-H, -W, -E, -R, -K, and ERV-9. The
expression of long transcripts is noteworthy as these are
most likely to contain intact packaging sequences and there-
fore be candidates for cross-packaging into PERV particles.
Our detection of HERV-R expression in 293 cells was
somewhat unexpected as this HERV was initially thought to
have an expression profile restricted to cells of placental and
embryonic origins (Boyd et al., 1993). However, more re-
cently, expression has also been detected in additional tissue
types (Andersson et al., 1998; Katsumata et al., 1998; Sibata
et al., 1997).
In addition to its broad HERV expression profile, we
chose the 293 cell line as our prototypic human cell because
it is the most permissive cell line for replication of PERV
that has been identified to date. In this regard, although
many other human cell lines and primary cells express
receptors for PERV and are also susceptible to PERV
pseudotypes, replication of PERV in these cells is either
extremely low or nonproductive (Patience et al., 1997;
Takeuchi et al., 1998; Wilson et al., 2000). Currently, the
block to PERV replication in these cells is not known. It
would prove interesting to expand the studies of HERV–
PERV copackaging into additional cell lines, especially if
lines could be identified that express alternative HERV
transcripts to 293 cells and can support PERV replication.
It is likely that the sequence divergence between PERV
and HERV affected the ability of HERV transcripts to be
cross-packaged into PERV virions. Increased rates of cross-
packaging tend to be observed if the two participating vi-
ruses have a high degree of nucleotide similarity, which is
in part due to the greater compatibility of the Gag proteins
of the nascent retroviral particle with the packaging se-
quences of the genomic RNAs (Katz and Skalka, 1990).
Although relatively little is known about HERV packaging
signals, because the overall sequence similarity between
PERV and HERV is low, it is likely that their packaging
sequences will also be divergent and will therefore interact
only very inefficiently, if at all. In support of this hypothe-
sis, previous studies have demonstrated that the RNAs of
several HERV groups are not packaged to a detectable level
into MLV-based particles (Patience et al., 1998b). Thus, our
results are consistent with previous studies indicating that
the efficiency of packaging of HERV transcripts into -ret-
rovirus particles is very low.
Interestingly, we found that MLV-derived transcripts
were packaged at relatively low efficiency by PERV parti-
cles (approximately one copy in 104 particles), despite the
significant sequence similarity that exists between these two
viruses. Thus, while our results confirm earlier studies that
demonstrate that replication-competent PERV can rescue
MLV-based vectors (Patience et al., 1997; Takeuchi et al.,
1998; Wilson et al., 2000), they suggest that this interaction
may be less efficient than previously thought. In contrast, it
should be noted that the correlation between genetic simi-
larity and the efficiency of cross-packaging does not always
apply. For example, although the packaging sequences of
murine leukemia virus and the murine retroelement VL30
are divergent at the nucleotide level, they both remain com-
patible with MLV Gag proteins (Torrent et al., 1994). Con-
sequently, when murine MLV-based retroviral packaging
cells are used to produce retroviral vectors, approximately
15% of particles contain VL30 RNAs (Patience et al.,
1998b). Thus, it appears difficult to predict the likelihood of
cross-packaging based solely on nucleotide sequence data.
Nevertheless, from a xenotransplantation safety perspective
it remains encouraging that we did not detect any cross-
packaging of any of the -retrovirus-related HERV groups
(HERV-H, -W, -R, -E, and ERV-9) nor the -retrovirus-
related HERV group, HERV-K.
The expression of packagable PERV genomes within the
293 cells might have affected the rate of packaging of
HERV transcripts into PERV particles. If HERV transcripts
are to be packaged into PERV particles, they must be able
to compete with high levels of PERV RNA expressed in an
infected cell. It might therefore prove informative to study
HERV genome cross-packaging into PERV particles in the
absence of packagable PERV genomes. Although more
artificial, the removal of competing PERV genomes might
allow for inefficient HERV cross-packaging events to be
detected. Such a study could be achieved if PERV-based
human packaging cells were developed, i.e., human cells
Table 2
Quantification of ERV sequences present in PERV particles produced from 293 cells
Retroviral transcript RT-PCR sensitivity (pg/l)a Peak fraction RNA concentration (pg/l) HERV:PERV ratiob
PERV 1250 1,280,000 NA
HERV-H 0.625 0.625 1:8,200,000
HERV-W 1.25 1.25 1:3,900,000
HERV-E 0.312 0.312 1:8,200,000
HERV-R 0.625 0.625 1:6,400,000
ERV-9 5.0 5.0 1:6,100,000
HERV-K 100 100 1:51,000
LacZ 0.039 100 1:38,400
NA, not applicable.
a Minimum input of transcribed standard RNA that resulted in a positive RT-PCR signal.
b Note that only minimum ratios can be presented because HERV RNAs were undetectable in the peak fractions. All ratios take into account the sizes of
the individual RT-PCR amplicons.
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engineered to express high levels of PERV Gag and Pol
proteins. Similarly, overexpression of individual HERV
transcripts in such packaging cells might also reveal ex-
tremely rare cross-packaging events.
In summary, we could not detect the cross-packaging of
several groups of HERV sequences into PERV particles
when using sensitive RT-PCRs. While these results are
reassuring, it might prove interesting to extend this study
with investigations of the copackaging of further HERV
groups and the production of PERV-based pseudotype
packaging cell lines. Ultimately, the risk that PERV–HERV
recombination represents in vivo can only be assessed fol-
lowing clinical xenotransplantation. However, our in vitro
results suggest that the risk is likely to be minimal.
Materials and methods
Cells
The human cell lines HEK293 and HepG2 were obtained
from the ATCC and maintained in Dulbecco’s modified
Eagle’s medium (Invitrogen Life Technologies, Baltimore,
MD) supplemented with 10% fetal bovine serum. 293/
PERV-A 14/220 cells were produced following the cocul-
ture of miniature swine PBMC with uninfected 293 cells.
The PERV-A isolate present in this culture contains recom-
binant PERV with the gag, pol, and env SU regions of
PERV-A, with the TM region of PERV-C.
Sucrose density gradients
The culture supernatant from approximately 4  106
cells (at confluency) was collected over a 16-h period,
0.45-m filtered, and fractionated by centrifugation through
12 ml linear sucrose density gradient (20 to 65%) at 100,000
g and 4°C for 16 h in an SW41 rotor (Sorval, Chicago, IL).
The gradients were collected in 500 l serial fractions prior
to analysis for density determination, reverse transcriptase
activity, and the presence of viral RNA transcripts by RT–
PCR. The density of the gradient fractions was determined
using a refractometer (Atago, Kirkland, WA).
Reverse transcriptase activity assays
The RT activity of gradient fractions was determined
using an ELISA-based assay (HS-kit Mn2, Cavidi Tech AB,
Sweden) in accordance with the manufacturer’s recommen-
dations. RT assessment was performed on 1:100 dilutions of
the gradient fraction.
RNA expression
DNA-free RNA was purified from cells and sucrose
gradient fractions using Trizol (Invitrogen Life Technolo-
gies) following the manufacturer’s instructions. The purity
of the RNA was confirmed by PCR analysis of RNA that
had not been subjected to reverse transcription. Quality of
the RNA was confirmed by amplification of either GAPDH
or PERV pol sequences as appropriate. Random-primed
cDNA was prepared using Superscript Kit (Invitrogen Life
Technologies). Following cDNA synthesis, PCR amplifica-
tion was performed on a 9600 thermal cycler (Perkin–
Elmer, Atlanta, GA). PCRs were performed with 30 cycles
of 94°C for 10 s, at 50°C 45 s, and 72°C for 30 s, with the
exception of the HERV-K PCR that used an annealing
temperature of 55°C. All oligonucleotide primers are listed
5–3. PCR products were visualized by ethidium bromide–
agarose gel electrophoresis.
For Northern blot analysis of HERV mRNA transcripts,
15 g of 293 cell total RNA was resolved on a 1% dena-
turing gel (0.6 M formaldehyde) in 1  MOPS, 0.2 M
formaldehyde running buffer. Neutral transfer of RNA was
performed in 10 SSC using the Turboblotter (Schleicher
& Schuell, Keene, NH) and Nytran Supercharge nylon
transfer membranes (Schleicher & Schuell) according to the
manufacturer’s guidelines. Prehybridization and hybridiza-
tion of membranes was performed at 42°C using the
ULTRAhyb hybridization buffer (Ambion, Houston, TX)
according to the manufacturer’s guidelines. The membrane
was sliced into a series of strips of equal size and RNA
loading, and each strip was probed using PCR-generated
32P-labeled probes derived by standard methodologies from
the RT-PCR amplicons produced using the primers and
conditions described above. The membranes were washed
twice for 30 min at 65°C with 0.1 SSC/0.2% SDS and
exposed to autoradiograph film for 72 h at 70°C.
RT-PCR sensitivity determination
ERV amplicons derived from 293 cell RNA were cloned
into pTOPO-TA (Invitrogen Life Technologies). The orien-
tation of the clones was determined and the constructs
linearized adjacent to the most 3 portion of the ERV insert
with NotI or BamHI to prevent runoff transcripts during
RNA synthesis. The linearized plasmids were gel purified
prior to the production of DNA-free RNA by SP6/T7 in
vitro transcription in accordance with the manufacturer’s
instructions (Maxiscript kit, Ambion). The quality of the
RNA was confirmed by gel electrophoresis and quantifica-
tion against RNA of known concentration (Invitrogen Life
Technologies) by ethidium bromide–ammonium acetate gel
spotting. Known amounts of the transcribed RNA were
titrated into the RT-PCR mixtures, enabling the sensitivity
of the assays to be determined. The combination of these
data, along with the dilution to which test samples could be
taken and still provide a positive RT-PCR signal, allowed
calculation of the concentration of RNA in the test samples.
Phylogenetic analysis and GenBank accession numbers
A neighbor-joining Phylogenetic analysis was performed
using the following GenBank sequences: PERV
(AF038599), HERV-E (M10976), HERV-R (M12140),
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ERV-9 (X57147), HERV-H (K01891), HERV-W
(AF135487), and HERV-K (M14123). The Phylip sequence
analysis package was used to create the phylogenetic tree.
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